GlobeNewsWire
17 Nov 2026, 12:45 UTC · 24m ago
Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update
Impact · against what's priced in
Medicenna Therapeutics' stock is likely to rise following positive Phase 1/2 data for MDNA11 in GI cancers. The 40% ORR and 80% DCR, combined with the completion of enrollment for 152 patients, provide a concrete clinical basis for advancing the candidate toward later-stage trials.
- MDNA+0.80
No priced-in read yet





